What are the current treatment options for CSU, how effective are they, and how many patients require alternatives beyond Xolair? How does Dupixent compare to Xolair, and what impact might its FDA approval have on the treatment landscape?

What are your thoughts on remibrutinib and BTK inhibitors in CSU treatment, and how do they compare to Xolair in terms of efficacy and placebo-adjusted effects? Will dermatologists be more inclined to adopt remibrutinib over other options?

How do KIT inhibitors compare in efficacy to existing CSU treatments, and does briquilimab show a meaningful safety advantage over barzolvolimab? How does briquilimab’s shorter half-life impact its potential benefits and safety profile?

What do you think about the seesawing effect observed in briquilimab's UAS7 reduction, and should efficacy be measured further into the dosing interval? Could a loading dose solve the issue of rebound effects, and will side effects like neutropenia and hair color changes affect its adoption?

Where do you see anti-KIT therapies fitting into the CSU treatment landscape, and will briquilimab be used primarily for Xolair-refractory patients? Could neutropenia concerns lead to required monitoring, and how excited are you about briquilimab’s potential? Could the oral KIT inhibitor from Blueprint outperform antibody-based KIT inhibitors?